Clinical use of [TIMP-2]•[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel

Overview of attention for article published in Critical Care, June 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

So far, Altmetric has seen 2 public wall posts from 2 users.

https://ccforum.biomedcentral.com/articles/10.1186/s13054-019-2504-8

The first FDA-approved test to assess risk for acute kidney injury (AKI), [TIMP-2]•[IGFBP7], is clinically available in many…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.